תוצאות חיפוש

Growth inhibition of pancreatic cancer cells by histone deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro a... מאת Wenwen Chien, Der‐Horng Lee, Yun Zheng, Peer Wuensche, Rosie Alvarez, Ling‐Wen Ding, Ahmed Aribi, Su Ming Thean, Ngan Doan, Jonathan W. Said, H. Phillip Koeffler

קבל טקסט מלא

A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors מאת Eugen Rempel, Lisa Hoelting, Tanja Waldmann, Nina V. Balmer, Stefan Schildknecht, Marianna Grinberg, John Antony Gaspar, Vaibhav Shinde, Regina Stöber, Rosemarie Marchan, Christoph van Thriel, Julia Liebing, Johannes Meisig, Nils Blüthgen, Agapios Sachinidis, Jörg Rahnenführer, Jan G. Hengstler, Marcel Leist

קבל טקסט מלא קבל טקסט מלא

Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer מאת Jason Kirk, Kevin Schaarschuch, Zafardjan Dalimov, Elena Lasorsa, Sheng‐Yu Ku, Swathi Ramakrishnan, Qiang Hu, Gissou Azabdaftari, Jianmin Wang, Роберто Пили, Leigh Ellis

קבל טקסט מלא קבל טקסט מלא

BIRC2/cIAP1 Is a Negative Regulator of HIV-1 Transcription and Can Be Targeted by Smac Mimetics to Promote Reversal of Viral Latency מאת Lars Pache, Míriam Santos Dutra, Adam M. Spivak, John Marlett, Jeffrey P. Murry, Young Sun Hwang, Ana M. Maestre, Lara Manganaro, Mitchell Vamos, Peter Teriete, Laura Martins, Renate König, Viviana Simon, Alberto Bosque, Ana Fernández-Sesma, Nicholas D. P. Cosford, Frederic D. Bushman, John A. T. Young, Vicente Planelles, Sumit K. Chanda

קבל טקסט מלא קבל טקסט מלא

Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma מאת Teru Hideshima, Francesca Cottini, Hiroto Ohguchi, Jana Jakubı́ková, Güllü Görgün, Naoya Mimura, YT Tai, Nikhil C. Munshi, Paul G. Richardson, K C Anderson

קבל טקסט מלא קבל טקסט מלא

Panobinostat for the treatment of multiple myeloma: the evidence to date מאת Sunil Sharma, Hanna Bailey, David D. Stenehjem

קבל טקסט מלא קבל טקסט מלא

Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat מאת Rikke Olesen, Selena Viganó, Thomas A. Rasmussen, Ole S. Søgaard, Zhengyu Ouyang, María J. Buzón, Arman Bashirova, Mary Carrington, Sarah Palmer, Christel R. Brinkmann, Xu G. Yu, Lars Østergaard, Martin Tolstrup, Mathias Lichterfeld

קבל טקסט מלא

Histone Deacetylase Inhibitors Inhibit Rhabdomyosarcoma by Reactive Oxygen Species–Dependent Targeting of Specificity Protein Transcription Factors מאת Erik Hedrick, Lisa E.S. Crose, Corinne M. Linardic, Stephen Safe

קבל טקסט מלא קבל טקסט מלא

<i>Ex Vivo</i>Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4⁺T Cells from Aviremic Patients מאת Adam M. Spivak, Alberto Bosque, Alfred H. Balch, David Smyth, Laura Martins, Vicente Planelles

קבל טקסט מלא

A phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group מאת Philippe A. Cassier, Anne Lefranc, Éric Amela, Christine Chevreau, B. Bui, A. Lecesne, Isabelle Ray‐Coquard, Sylvie Chabaud, Nicolas Penel, Yann Bergé, Julien Dômont, Antoîne Italiano, Florence Duffaud, A-C Cadore, Valentine Polivka, Jean‐Yves Blay

קבל טקסט מלא קבל טקסט מלא

Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors מאת Michael Bots, Inge Verbrugge, Benjamin P. Martin, Jessica M. Salmon, Margherita Ghisi, Adele Baker, Kym L. Stanley, Jake Shortt, Gert J. Ossenkoppele, Johannes Zuber, Amy Rappaport, Peter Atadja, Scott W. Lowe, Ricky W. Johnstone

קבל טקסט מלא

Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide) מאת Chang Xia, Roberto A. Leon‐Ferre, Douglas Laux, Jeremy Michael Deutsch, Bruce A. Smith, Melanie Frees, Mohammed Milhem

קבל טקסט מלא קבל טקסט מלא

A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer מאת Dana E. Rathkopf, Joel Picus, Arif Hussain, Susan Ellard, Kim Nguyen, Thomas Nydam, E. Allen-Freda, Kaushal Mishra, Maria Grazia Porro, Howard I. Scher, George Wilding

קבל טקסט מלא

Profile of panobinostat and its potential for treatment in solid tumors: an update מאת Madhurima Anne, Daniel de Sammartino, Myra F. Barginear, Daniel R. Budman

קבל טקסט מלא קבל טקסט מלא

Manipulation of B-cell responses with histone deacetylase inhibitors מאת Michaela Waibel, Ailsa J. Christiansen, Margaret L. Hibbs, Jake Shortt, Sarah A. Jones, Ian Simpson, Amanda Light, Kristy O’Donnell, Eric F. Morand, David M. Tarlinton, Ricky W. Johnstone, Edwin D. Hawkins

קבל טקסט מלא קבל טקסט מלא

Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemia מאת Christopher Parrish, Gina B. Scott, G Migneco, Karen J. Scott, Lynette P. Steele, Elizabeth J. Ilett, Emma J. West, Kathryn Hall, Peter J. Selby, David L. Buchanan, Abraham Varghese, Mark S. Cragg, Matt Coffey, Peter Hillmen, Alan Melcher, Fiona Errington‐Mais

קבל טקסט מלא קבל טקסט מלא

Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: implications for therapy מאת Mamta Gupta, Jingjing Han, Mary Stenson, L Wellik, Thomas E. Witzig

קבל טקסט מלא

Panobinostat (LBH589)-induced acetylation of tubulin impairs megakaryocyte maturation and platelet formation מאת Camelia Iancu‐Rubin, David Gajzer, Goar Mosoyan, Faye Feller, John Mascarenhas, Ronald Hoffman

קבל טקסט מלא קבל טקסט מלא

Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome מאת Puay Hoon Tan, Andrew H. Wei, Sridurga Mithraprabhu, Nicholas J. Cummings, Hong Bo Liu, Michelle Perugini, Kate Reed, S Avery, S. Patil, Patricia Walker, Peter Mollee, Andrew Grigg, Richard J. D’Andrea, Anthony E. Dear, Andrew Spencer

קבל טקסט מלא קבל טקסט מלא

Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma מאת Jennifer E. Amengual, Sean Clark-Garvey, Matko Kalac, Luigi Scotto, Enrica Marchi, Ellen Neylon, Paul Johannet, Ying Wei, Jasmine Zain, Owen A. O’Connor

קבל טקסט מלא